Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5365180 | 0.91 | MAPK8 (0.59) | MAPK8KMT2ALMNAHPGDSMN1; SMN2 | |
| SCHEMBL3086802 | 0.90 | MAPK8 (0.62) | MAPK8KMT2APTGER4LMNAHPGD | |
| SCHEMBL7317640 | 0.89 | MAPK8 (0.75) | MAPK8KMT2APTGER4LMNAHPGD | |
| SCHEMBL7368970 | 0.88 | MAPK8 (0.60) | MAPK8KMT2ALMNAHPGDSMN1; SMN2 | |
| SCHEMBL6906234 | 0.87 | MAPK8 (0.61) | MAPK8KMT2APTGER4LMNAHPGD | |
| SCHEMBL5362190 | 0.87 | PDE4A (0.55) | MAPK8KMT2ALMNA | |
| SCHEMBL5353948 | 0.87 | MAPK8 (0.58) | MAPK8PTGER4LMNAHPGDSMN1; SMN2 | |
| SCHEMBL7168843 | 0.87 | MAPK8 (0.72) | MAPK8KMT2APTGER4 | |
| SCHEMBL7371446 | 0.86 | LMNA (0.72) | MAPK8KMT2ALMNAHPGDSMN1; SMN2 | |
| SCHEMBL7682147 | 0.85 | MAPK8 (0.61) | MAPK8KMT2APTGER4LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1229034-B1 | Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes | PFIZER PROD INC (US) | 2005-04-13 | — | — | EP | claimed |
| US-20040171798-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC | 2004-09-02 | — | — | US | claimed |
| US-20020111495-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC. | 2002-08-15 | — | — | US | claimed |
| EP-1229034-A1 | Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes | Pfizer Products Inc. (US) | 2002-08-07 | — | — | EP | claimed |
| US-7250518-B2 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250518-B2 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250518-B2 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC. (US) | 2007-07-31 | — | — | US | disclosed |
| EP-1229034-B1 | Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes | PFIZER PROD INC (US) | 2005-04-13 | — | — | EP | disclosed |
| EP-1229034-B1 | Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes | PFIZER PROD INC (US) | 2005-04-13 | — | — | EP | disclosed |
| US-20040171798-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC | 2004-09-02 | — | — | US | disclosed |
| US-20020111495-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | PFIZER INC. | 2002-08-15 | — | — | US | disclosed |
| EP-1229034-A1 | Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes | Pfizer Products Inc. (US) | 2002-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171798-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | NOX3, PDE4A, NOX1 | MAPK8 2655/4885KMT2A 3049/4885PTGER4 95/4885 |
| US-20020111495-A1 | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes | NOX3, NOX1, NOX4 | MAPK8 2943/4885KMT2A 3442/4885PTGER4 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.